Un caso de pioderma gangrenoso asociado a bevacizumab: papel de la angiogénesis en su etiopatogenia

Iván Maray-Mateos; Cristina Álvarez-Asteinza; Mónica Carbajales-Álvarez; Ana Lozano-Blázquez

doi:10.7399/fh.11705

Un caso de pioderma gangrenoso asociado a bevacizumab: papel de la angiogénesis en su etiopatogenia

Iván Maray-Mateos, Cristina Álvarez-Asteinza, Mónica Carbajales-Álvarez, Ana Lozano-Blázquez

Resumen

Texto completo:

PDF (English) PDF

Referencias

Ahn C, Negus D, Huang W. Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol. 2018;14(3):225-33.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M. Colorectal cancer. Lancet. 2019;394(10207):1467-80.

Ara M, Pastushenko E. Antiangiogenic Agents and the Skin: Cutaneous Adverse Effects of Sorafenib, Sunitinib, and Bevacizumab. Actas Dermosifiliogr. 2014;105(10):900-12.

European Medicines Agency. Eudravigilance, European database of suspected adverse drug reactions [Internet] [accessed 06/19/2021]. Available at: https://www.adrreports.eu/

Naranjo CA, Busto U, Sellers EM, Sandor PM, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.

Kridin K, Cohen A, Amber K. Underlying Systemic Diseases in Pyoderma Gangrenosum: A Systematic Review and Meta-Analysis. Am J Clin Dermatol. 2018;19(4):479-87.

Gupta A, Ortega-Loayza A. Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. Ann Hematol. 2019;98(9):2247-8.

Chua R, Mackelfresh J, Cohen C, Varma V, Fried L, Arbiser J. Disseminated pyoderma gangrenosum: Role for vascular endothelial growth factor and hypoxia inducible factor-2. J Am Acad Dermatol. 2009;61(4):730-2.

Wang JY, French LE, Shear NH, Amiri A, Alavi A. Drug-Induced Pyoderma Gangrenosum: A Review. Am J Clin Dermatol. 2018;19:67- 77.

Ellis C, Morrison M, LaFond A, Fivenson D. An interesting case of pyoderma gangrenosum. J Am Acad Dermatol. 2016;74(5 Supl):AB292.

DOI: http://dx.doi.org/10.7399%2Ffh.11705